TITLE:
UGT2B17 status and risk of prostate cancer: A meta-analysis
AUTHORS:
Marce-Amara Kpoghomou, Fatch W. Kalembo, Joella Eldie Soatiana, Ghose Bishwajit, Wei Sheng
KEYWORDS:
Prostate Cancer; UGT2B17 Status; Polymorphism; Meta-Analysis
JOURNAL NAME:
Open Journal of Preventive Medicine,
Vol.3 No.4,
June
26,
2013
ABSTRACT: Objective: Recent studies on the association between Uridine diphosphoglucuronosyl tranferases (UGT) 2B17 status and risk of prostate cancer (PCa) showed inconclusive results. To clarify this possible association, we conducted a meta-analysis of published studies. Methods: We searched published literature from PubMed, Embase, Google Scholar and China National Knowledge Infrastructure (CNKI). According to our inclusion criteria, studies that observed the association between UGT2B17 status and PCa risk were included. The principal outcome measure was the adjusted odds ratio (OR) with 95% confidence interval (CI) for the risk of PCa associated with UGT2B17 status. Results: A total of 6 studies with 7029 subjects (3839 cases and 3190 controls) were eligible for inclusion in the meta-analysis. Overall, there was a significant association between UGT2B17 status and increased risk of prostate cancer (OR = 1.74, 95% CI 1.14 - 2.64, P 0.001). Similar results were found in the subgroup analyses by ethnicity and types of controls. Conclusion: This meta-analysis demonstrates that UGT2B17 status is associated with prostate cancer susceptibility, and it contributes to increased risk of prostate cancer.